Clinical trial: A novel high-dose 1 g mesalamine suppository (salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis

Inflammatory Bowel Diseases

Volumn 16, Issue 11, 2010, Pages 1947-1956

  Andus, Tilo ^a   Kocjan, Andreas ^b   Müser, Moritz ^b   Baranovsky, Andrey ^c   Mikhailova, Tatyana L ^d   Zvyagintseva, Tatyana D ^e   Dorofeyev, Andrey E ^f   Lozynskyy, Yurii S ^g   Cascorbi, Ingolf ^h   Stolte, Manfred ⁱ   Vieth, Michael ⁱ   Dilger, Karin ^j   Mohrbacher, Ralf ^j   Greinwald, Roland ^j  

^a Klinikum Stuttgart Krankenhaus Bad Cannstatt   (Germany)

^b Facharztpraxis für Innere Medizin   (Germany)

^c NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^d State Scientific Centre of Coloproctology   (Russian Federation)

^e KHARKIV MEDICAL ACADEMY OF POSTGRADUATE EDUCATION   (Ukraine)

^f DONETSK NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^g Lviv Regional Clinical Hospital   (Ukraine)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ INSTITUTE OF PATHOLOGY   (Germany)

^j NONE

more..

Author keywords

distal ulcerative colitis; mesalamine; N acetyltransferase; once daily; proctitis; suppository

Indexed keywords

MESALAZINE;

ADULT; AGED; ANXIETY; ARTERY EMBOLISM; ARTHRALGIA; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION URGENCY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FECES ANALYSIS; FEMALE; FLATULENCE; FLU LIKE SYNDROME; HEADACHE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SUBCLAVIAN ARTERY EMBOLISM; SUPPOSITORY; SYMPTOM; THROMBOCYTE COUNT; TREATMENT DURATION; ULCERATIVE COLITIS; ULCERATIVE PROCTITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PATIENT PREFERENCE; PROCTITIS; REMISSION INDUCTION; SINGLE-BLIND METHOD; SUPPOSITORIES; YOUNG ADULT;

EID: 78249266327     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21258     Document Type: Article

References (40)

1. Carter MJ, Lobo AJ, Travis SPL, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004; 53: V1-V16.
2. Hanauer SB,. Medical therapy for ulcerative colitis 2004. Gastroenterology. 2004; 126: 1582-1592.
3. Hanauer SB,. Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2004; 20: 60-65.
4. Hoffmann JC, Zeitz M, Bischoff SC, et al. Diagnosis and therapy of ulcerative colitis: Results of an evidence based consensus conference by the German Society of Digestive and Metabolic Diseases and the Competence Network on Inflammatory Bowel Disease (in German). Z Gastroenterol. 2004; 42: 979-1032.
5. Kornbluth A, Sachar DB,. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004; 99: 1371-1385.
6. Travis SPL, Stange EF, Lémann M, et al. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohn Colitis. 2008; 2: 24-62.
7. Schwab M, Reynders V, Loitsch S, et al. PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis. 2008; 29: 1407-1414.
8. Kaufman J, Griffiths TA, Surette MG, et al. Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression. Inflamm Bowel Dis. 2009; 15: 985-996.
9. Marshall JK, Irvine EJ,. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther. 1995; 9: 293-300.
10. Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000; 95: 1263-1276.
11. Marshall JK, Irvine EJ,. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol. 2000; 95: 1628-1636.
12. Xin HW, Schwab M, Klotz U,. Transport studies with 5-aminosalicylate. Eur J Clin Pharmacol. 2006; 62: 871-875.
13. Hein DW, Doll MA, Rustan TD, et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis. 1993; 14: 1633-1638.
14. Kane SV,. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006; 23: 577-585.
15. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMX. Inflamm Bowel Dis. 2005; 11: 421-427.
16. Loftus EV Jr,. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006; 12: 1107-1113.
17. Gionchetti P, Rizzello F, Venturi A, et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther. 1997; 11: 1053-1057.
18. Campieri M, De Franchis R, Bianchi-Porro G, et al. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol. 1990; 25: 663-668.
19. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987; 92: 1894-1898.
20. Rachmilewitz D,. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989; 298: 82-86.
21. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991; 32: 174-178.
22. Hanauer SB, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993; 88: 1188-1197.
23. Cascorbi I, Roots I, Brockmoller J,. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cancer Res. 2001; 61: 5051-5056.
24. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001; 69: 169-174.
25. Bruhn C, Brockmöller J, Cascorbi I, et al. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol. 1999; 58: 1759-1764.
26. Cascorbi I, Drakoulis N, Brockmöller J, et al. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995; 57: 581-592.
27. Cascorbi I,. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther. 2006; 112: 457-473.
28. O'Brien PC, Fleming TR,. A multiple testing procedure for clinical trials. Biometrics. 1979; 35: 549-556.
29. ADDPLAN GmbH. ADDPLAN Adaptive Designs, Plans and Analyses. Release 2.0. Germany: 2003.
30. Farrington CP, Manning G,. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990; 9: 1447-1454.
31. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126: 451-459.
32. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004; 53: 1813-1816.
33. Ngo Y, Gelinet JM, Ivanovic A, et al. [Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis. A double-blind versus placebo randomized trial.] Gastroenterol Clin Biol. 1992; 16: 782-786.
34. Lucidarme D, Marteau P, Foucault M, et al. Efficacy and tolerance of mesalazine suppositories vs. hydro-cortisone foam in proctitis. Aliment Pharmacol Ther. 1997; 11: 335-340.
35. Marteau P, Florent C, and the French Pentasa Study Group. Comparative, open, randomized trial of the efficacy and tolerance of slow-release 5-ASA suppositories once daily versus conventional 5-ASA suppositories twice daily in the treatment of active cryptogenic proctitis. Am J Gastroenterol. 2000; 95: 166-170.
36. Lamet M, Ptak T, Dallaire C, et al. Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. Inflamm Bowel Dis. 2005; 11: 625-630.
37. Dilger K, Trenk D, Rössle M, et al. A clinical trial on absorption and N-Acetylation of oral and rectal mesalazine. Eur J Clin Invest. 2007; 37: 558-565.
38. Campieri M, Gionchetti P, Belluzzi A, et al. Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial. Int J Colorectal Dis. 1990; 5: 79-81.
39. Loftus EV, Kane SV, Bjorkman D,. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004; 19: 179-189.
40. Ilett KF, Ingram DM, Carpenter DS, et al. Expression of monomorphic and polymorphic N-acetyltransferases in human colon. Biochem Pharmacol. 1994; 47: 914-917.